Faculty

Work Experience

• Aug 1988 – Aug 2002: The Second Affiliated Hospital of Lanzhou University, Associate Chief Pharmacist, Associate Professor

• Aug 2005 – Feb 2014: Peking University Third Hospital, Chief Pharmacist, Associate Professor

• Mar 2014 – Jun 2015: Beijing Tsinghua Changgung Hospital, Director of Pharmacy Department, Chief Pharmacist, Associate Professor

• Jun 2015 – Present: Beijing Tsinghua Changgung Hospital, Director of Clinical Pharmacy Department, Chief Pharmacist, Associate Professor

1. Pharmacogenomics in Organ Transplantation

2. Pharmacogenomics of Thromboembolic Diseases

3. Pharmacotherapy of Infectious Diseases

4. Pharmacotherapy of Cardiovascular Diseases

5. Pharmacotherapy in the Elderly Population

1.Li Y, Tang HL, Hu YF*, Xie HG, The Gain-of-Function Variant Allele CYP2C19*17: A Double-Edged Sword Between Thrombosis and Bleeding in Clopidogrel-Treated Patients, J Thromb Haemost, 2012, 10(2):199-206

2.Yao Ya, Ma CH, Tang HL, Hu YF*, Influence of follicle-stimulating hormone receptor (FSHR) Ser680Asn polymorphism on ovarian function and in-vitro fertilization outcome: A meta-analysis, Mol Genet Metab, 2011, 103: 388-393

3.Tang HL, Xie HG, Yao Y, Hu YF*, Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non-expressers than expressers, Pharmacogenetics and Genomics, 2011, 21(11): 713–720

4.Tang HL, Ma LL, Xie HG, Zhang T, Hu YF*, Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis, Pharmacogenetics and Genomics, 2010,20(9): 525-531

5.Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH, Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation, Clin Exp Pharmacol Physiol, 2006,33(11):1093-1098, Clin Exp Pharmacol Physiol, 2006,33(11):1093-1098

6.Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH, Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects, Xenobiotica, 2007, 37 (3):315-327

7.Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH, CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population, Clin Chim Acta, 2005,353(1-2):187-192

8.谢吉科,颜妍,陈朋,胡永芳.北京清华长庚医院门诊老年患者多重用药调查及潜在不适当用药分析[J].临床药物治疗杂志,2018,16(11):52-55+60

1. (Translation Committee Member) Li DK, Jin YY, Tang G (Chief Editors); Chen W, Chen XG, Hu YF, et al. (49 Committee Members); Cai Y, et al. (156 Translators). Martindale: The Complete Drug Reference (35th Edition, Chinese Translation). Chemical Industry Press; Jan 2009. 2110 pp.

2. (Deputy Chief Translator) Zhai SD (Chief Translator); Zhao RS, Hu YF (Deputy Chief Translators); Zhang XL, Zhao RS, Duan JL, Zhang L, Lou HG, Zhou X, Ying YQ, Liu F, Zhang L, Zhang WY, Wang XN, Yang YH, Yang L, Shu Z, Hu YF, Wang D, Zhang C, Li XG, Zhang HY. Oxford Handbook of Clinical Pharmacy (Chinese Translation). People's Medical Publishing House; May 2006. 700 pp.

1. "Experimental Research on Bioengineered Drug - Basic Fibroblast Growth Factor (bFGF) and Re-evaluation of the Efficacy of Cerebroprotein Hydrolysate Injection": Third Prize, Gansu Provincial Higher Education Institutions Science and Technology Progress Award (First Contributor), 2002.

1. Standing Committee Member, Pharmacogenomics Professional Committee, Chinese Pharmacological Society (Oct 2019 - Present)

2. Standing Committee Member, Diabetes Professional Committee, China Medicine Education Association (Sep 2019 - Present)